Strides Arcolab receives USFDA approval for Acetazolamide Injection

10 May 2012 Evaluate

Strides Arcolab (Strides) has received ANDA approval from USFDA for Acetazolamide Injection USP, 500 mg/ vial (preservative free) in lyophilized format. The product is expected to be launched shortly. According to IMS, the 2011 US market for Injectable Acetazolamide approximates to $10 million with only one active player.

Acetazolamide is the fourteenth product approved under the Sagent - Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.

Acetazolamide is used for adjunctive treatment of - edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

878.65 -7.00 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×